Cargando…
Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization
Fever is one of the most common symptoms of illness in infants and represents a clinical challenge due to the potential for serious bacterial infection. As delayed treatment for these infections has been correlated with increased morbidity and mortality, broad-spectrum [Formula: see text]-lactam ant...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
IEEE
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003167/ https://www.ncbi.nlm.nih.gov/pubmed/27602307 http://dx.doi.org/10.1109/JTEHM.2016.2573305 |
_version_ | 1782450618554646528 |
---|---|
collection | PubMed |
description | Fever is one of the most common symptoms of illness in infants and represents a clinical challenge due to the potential for serious bacterial infection. As delayed treatment for these infections has been correlated with increased morbidity and mortality, broad-spectrum [Formula: see text]-lactam antibiotics are often prescribed while waiting for microbiological lab results (1–3 days). However, the spread of antibiotic resistance via the [Formula: see text]-lactamase enzyme, which can destroy [Formula: see text]-lactam antibiotics, has confounded this paradigm; empiric antibiotic regimens are increasingly unable to cover all potential bacterial pathogens, leaving some infants effectively untreated until the pathogen is characterized. This can lead to lifelong sequela or death. Here, we introduce a fluorescent, microfluidic assay that can characterize [Formula: see text]-lactamase derived antibiotic susceptibility in 20 min with a sensitivity suitable for direct human specimens. The protocol is extensible, and the antibiotic spectrum investigated can be feasibly adapted for the pathogens of regional relevance. This new assay fills an important need by providing the clinician with hitherto unavailable point of care information for treatment guidance in an inexpensive and simple diagnostic format. |
format | Online Article Text |
id | pubmed-5003167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | IEEE |
record_format | MEDLINE/PubMed |
spelling | pubmed-50031672016-09-06 Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization IEEE J Transl Eng Health Med Article Fever is one of the most common symptoms of illness in infants and represents a clinical challenge due to the potential for serious bacterial infection. As delayed treatment for these infections has been correlated with increased morbidity and mortality, broad-spectrum [Formula: see text]-lactam antibiotics are often prescribed while waiting for microbiological lab results (1–3 days). However, the spread of antibiotic resistance via the [Formula: see text]-lactamase enzyme, which can destroy [Formula: see text]-lactam antibiotics, has confounded this paradigm; empiric antibiotic regimens are increasingly unable to cover all potential bacterial pathogens, leaving some infants effectively untreated until the pathogen is characterized. This can lead to lifelong sequela or death. Here, we introduce a fluorescent, microfluidic assay that can characterize [Formula: see text]-lactamase derived antibiotic susceptibility in 20 min with a sensitivity suitable for direct human specimens. The protocol is extensible, and the antibiotic spectrum investigated can be feasibly adapted for the pathogens of regional relevance. This new assay fills an important need by providing the clinician with hitherto unavailable point of care information for treatment guidance in an inexpensive and simple diagnostic format. IEEE 2016-06-29 /pmc/articles/PMC5003167/ /pubmed/27602307 http://dx.doi.org/10.1109/JTEHM.2016.2573305 Text en 2168-2372 © 2016 IEEE. Translations and content mining are permitted for academic research only. Personal use is also permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information. |
spellingShingle | Article Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization |
title | Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization |
title_full | Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization |
title_fullStr | Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization |
title_full_unstemmed | Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization |
title_short | Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization |
title_sort | guiding empiric treatment for serious bacterial infections via point of care [formula: see text]-lactamase characterization |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003167/ https://www.ncbi.nlm.nih.gov/pubmed/27602307 http://dx.doi.org/10.1109/JTEHM.2016.2573305 |
work_keys_str_mv | AT guidingempirictreatmentforseriousbacterialinfectionsviapointofcareformulaseetextlactamasecharacterization AT guidingempirictreatmentforseriousbacterialinfectionsviapointofcareformulaseetextlactamasecharacterization AT guidingempirictreatmentforseriousbacterialinfectionsviapointofcareformulaseetextlactamasecharacterization AT guidingempirictreatmentforseriousbacterialinfectionsviapointofcareformulaseetextlactamasecharacterization |